Wyeth Pharmaceuticals,a division of Wyeth (NYSE: WYE), this week presented for the first timephase 3 data and results from other studies concerning its investigationaldrug for major depressive disorder (MDD), desvenlafaxine succinate(DVS-233), a novel serotonin-norepinephrine reuptake inhibitor (SNRI) atthe 2006 American Psychiatric Association Annual Meeting in Toronto. [click link for full article]
Popularity: unranked [?]
